Regulation of type I interferon signature by VGLL3 in the fibroblast-like synoviocytes of rheumatoid arthritis patients via targeting the Hippo pathway

Yu Du1, Ran Cui1, Na Tian1, Miao Chen1, Xian-Long Zhang2 and Sheng-Ming Dai1*

Abstract

Background: The upregulation of interferon (IFN)-stimulated genes induced by type I IFNs (namely type I IFN signature) in rheumatoid arthritis (RA) patients had implications in early diagnosis and prediction of therapy responses. However, factors that modulate the type I IFN signature in RA are largely unknown. In this study, we aim to explore the involvement of VGLL3, a homologue of the vestigial-like gene in Drosophila and a putative regulator of the Hippo pathway, in the modulation of type I IFN signature in the fibroblast-like synoviocytes (FLS) of RA patients.

Methods: FLS were isolated from RA and osteoarthritis (OA) patients. Expression of VGLL3 in the synovial tissues and FLS was analyzed by immunohistochemistry and PCR. RNA sequencing was performed in RA-FLS upon VGLL3 overexpression. The expression of IFN-stimulated genes was examined by PCR and Western blotting.

Results: VGLL3 was upregulated in the RA synovium and RA-FLS compared to OA. Overexpression of VGLL3 promoted the expression of IFN-stimulated genes in RA-FLS. The expression of STAT1 and MX1 was also upregulated in RA synovium compared to OA and was associated with the expression of VGLL3 in RA and OA patients. VGLL3 promoted the IRF3 activation and IFN-β1 expression in RA-FLS. Increased IFN-β1 induced the expression of IFN-stimulated genes in RA-FLS in an autocrine manner. VGLL3 also modulated the expression of the Hippo pathway molecules WWTR1 and AMOTL2, which mediated the regulation of IRF3 activation and IFN-β1 production by VGLL3 in RA-FLS.

Conclusions: VGLL3 drives the IRF3-induced IFN-β1 expression in RA-FLS by inhibiting WWTR1 expression and subsequently promotes the type I IFN signature expression in RA-FLS through autocrine IFN-β1 signaling.

Keywords: Rheumatoid arthritis, Interferon beta, Type I interferon signature, Hippo pathway

Background

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that predominantly affects the diarthrodial joints, characterized by synovitis and destructive erosion of cartilage and bone [1]. The chronic synovitis in RA exhibits distinctive features, including the expansion of the fibroblast-like synoviocytes (FLSs) population, infiltration of leucocytes, and elevated expression of inflammatory mediators such as cytokines and chemokines [2]. Type I interferons (IFNs), predominantly consisting of α and β subtypes, were initially recognized as master inducers of anti-viral responses. Nevertheless, growing evidence revealed their potential role in the pathogenesis of RA [3, 4]. After engagement with the IFN-α receptor...
induced IFN-I and ISGs production [22]. WWTR1 was recently reported to inhibit the virus-
in the RA synovial fluid and synovium [11, 12]. Furthermore, STAT1, which is an IFN signal transducer and activator of transcription 1 (STAT1), STAT2, and IFN regulatory factor 9 (IRF9). The ISGF3 complex subsequently induces the expression of a broad spectrum of IFN-stimulated genes (ISGs) [5]. ISGs belong to a set of nearly two thousand genes regulated by different IFNs in a subtype-dependent manner [6, 7]. The upregulation of ISGs induced by type I IFNs (namely type I IFN signature) participated in the RA pathogenesis and had implications in early diagnosis and prediction of therapy responses in RA patients [8]. Among the ISGs, cytokines like tumor necrosis factor ligand superfamily member 13B (TNFSF13B; also known as B cell-activating factor, BAFF), and chemokines such as CCL5, CXCL10, and CXCL12, could be continuously secreted by FLSs in the inflamed RA synovium. They are at least partly responsible for the recruitment of leucocytes to the synovium and the perpetuation of the local inflammation [9, 10]. Furthermore, STAT1, which is an IFN signal transducer and an ISG, was found to be upregulated and activated in the RA synovial fluid and synovium [11, 12]. A previous study also showed a type I IFN-dependent activation of STAT1 in RA-FLS [13]. However, the type I IFN signature showed heterogeneity in RA, because it was only found in a subgroup of RA patients [14–16]. The type I IFN signature in the peripheral blood has been recognized as a biomarker of preclinical RA [17]. It was also reported that type I IFN signature negatively predicted the clinical response to rituximab in RA patients [18]. Factors that modulate the type I IFN signature in RA are largely unknown, which impedes the application of type I IFN signature during clinical practice.

There is evidence of the crosstalk between type I IFN signaling and the Hippo pathway [19]. The core proteins of the Hippo pathway in vertebrates are Yes-associated protein (YAP) and its paralog WW domain-containing transcription regulator 1 (WWTR1), which is also known as transcriptional coactivator with PDZ-binding motif (TAZ). Upon activation of this pathway, the upstream large tumor suppressor kinase 1/2 (LATS1/2) phosphorylates YAP/WWTR1, which results in their degradation in the proteasome. Once the upstream signaling is inactivated, YAP/WWTR1 translocates into the nucleus, leading to transcription of genes that contribute to development, tumorigenesis, and homeostasis [20, 21]. YAP/WWTR1 was recently reported to inhibit the virus-induced IFN-I and ISGs production [22].

Recently, vestigial family member 3 (VGLL3) has been predicted to have possible connections with the Hippo pathway. VGLL3 is a homologue of the vestigial-like gene in Drosophila. It is a putative transcriptional cofactor for TEA domain-containing transcription factors (TEADs) [23], and it has been implicated in adipocyte differentiation, myogenesis, tumor, and autoimmune diseases [24–26]. Hori et al. revealed that VGLL3 could promote cancer cell proliferation by inhibiting YAP/WWTR1 [27]. VGLL3 was also required in the IFN-α-induced BAFF expression and pathogenesis of systemic lupus erythematosus (SLE) [28]. However, the role of VGLL3 in RA remains unknown. We hypothesized that VGLL3 might be involved in the modulation of type I IFN signature in RA.

Here, we first revealed the upregulation of VGLL3 in RA synovium and further demonstrated that VGLL3 drove the IRF3-induced IFN-β secretion in RA-FLS by inhibiting WWTR1 expression and subsequently promoted type I IFN signature expression through autocrine IFN-β signaling.

**Methods**

**Collection of synovial tissues and culture of human FLS**

Synovial tissues were collected from ten RA patients (all females, mean age 60.2 ± 11.8 years) and five osteoarthritis (OA) patients (all females, mean age 64.2 ± 7.1 years) diagnosed according to the 1987 ACR classification criteria for RA [29] or 1986 revised ACR classification criteria for knee OA [30] during total knee arthroplasty in the department of orthopedic surgery of Shanghai Jiao Tong University Affiliated Sixth People's Hospital. All the patients were not receiving any antirheumatic drug therapy at the time of surgery. Informed consent was obtained from all patients before sample collection. This study complied with the Declaration of Helsinki (1964), and the research was approved by the Ethic Committee of Shanghai Jiao Tong University Affiliated Sixth People's Hospital. FLS were isolated from synovial tissues by digesting with 1 mg/mL type II collagenase (Merck Millipore, MA, USA) and incubated with rabbit anti-VGLL3 antibody (1:100, 13750-1-AP, Proteintech, Wuhan, China), rabbit anti-MX1 antibody (1:100, 13750-1-AP, Proteintech, Wuhan, China), rabbit anti-STAT1 antibody (1:250, ab109320, Abcam, Cambridge, UK), and rabbit IgG (isotype control, 12-370, Merck Millipore, MA, USA) at 4 °C.
overnight. After washing with phosphate-buffered saline (PBS) three times, sections were incubated with horse-radish peroxidase (HRP)-conjugated donkey anti-rabbit antibody (1:1000, Jackson ImmunoResearch Labs, PA, USA) and further stained with diaminobenzidine (DAB, Beyotime Biotechnology, Shanghai, China). For immuno-fluorescence staining, cultured FLS were fixed in PFA and permeabilized with 0.5% Triton X-100. After blocking with 10% donkey serum, cells were incubated with rabbit anti-VGLL3 antibody (1:500, ab83555, Abcam, Cambridge, UK), rabbit anti-STAT1 antibody (1:250, ab109320, Abcam, Cambridge, UK), rabbit anti-phospho-STAT1 antibody (1:1000, ab76493, Abcam, Cambridge, UK) at 4°C overnight. The next day, cells were washed with PBS and incubated with Alexa Fluor 555-conjugated donkey anti-rabbit antibody (1:500, ab150130, Abcam, Cambridge, UK) and mounted with Antifade Mounting Medium with DAPI (4′,6-diamidino-2-phenylindole) (Beyotime Biotechnology, Shanghai, China). Images were captured with a microscope (Olympus, Tokyo, Japan) (magnification ×200) with an equal time of exposure.

**siRNA transfection and lentivirus transduction**

VGLL3 siRNA or WWTR1 siRNA were transfected into RA-FLS to knock down the expression of these genes. Scramble siRNA was used as the negative control. All the siRNA were synthesized by Ribobio (Guangzhou, China). The target sequences are as follows: scramble siRNA, TTC TCC GAA CGT GTC ACG T; VGLL3 siRNA, GGT CAG TAG TGG ATG AAC A; WWTR1 siRNA, CGA TGA ATC AGC CTC TGA A. siRNA was transfected into FLS using Lipofectamine 2000 (Thermo Fisher Scientific, MA, USA) transfection reagent following the manufacturer’s instructions. For VGLL3 overexpression, full-length VGLL3 was cloned into lentiviral vectors (pHBLV-CMV-MCS-3FLAG-EF1-ZsGreen-T2A-PURO) via standard molecular biology techniques. Lentivirus was produced by co-transfecting 293T cells with VGLL3 lentiviral vectors or control vectors together with packaging plasmids. The lentivirus solution was concentrated by ultracentrifugation. The titers of control and overexpression lentivirus solutions were determined by infecting 293T cells. Briefly, 293T cells were seeded in a 96-well plate at a density of 10^4 cells/well and added with gradient diluted virus solutions in different wells. The titers of viruses were calculated after 72 h with 10%-50% GFP-positive cells using the following formula:

\[
\text{Titers (TU/mL)} = \frac{\text{cell counts per well}}{\text{percentage of GFP positive cells}} \times \text{MOI} \times \frac{1}{10^3} \times \text{virus dilution ratio}
\]

**RNA extraction, reverse transcription PCR (RT-PCR), and real-time quantitative PCR (qPCR)**

Total RNA was extracted by TRIZol reagent (Thermo Fisher Scientific, MA, USA) according to the manufacturer’s instructions. cDNA was generated using the ReverTra Ace qPCR RT Master Mix with gDNA Remover kit (Toyobo, Osaka, Japan). RT-PCR was conducted by 2×Hieff™ PCR Master Mix (Yeasen, Shanghai, China) followed by agarose gel electrophoresis. qPCR was performed using SYBR Green Realtime PCR Master Mix kit (Toyobo, Osaka, Japan). The primer sequences are listed in Table 1.

| Gene symbol | Forward primer (5′-3′) | Reverse primer (5′-3′) |
|-------------|------------------------|------------------------|
| β-actin     | GGACCTGACTGACTCCTCAT   | CGTACGACACCTTCCTTAAT   |
| GAPDH       | GAATGGGCGAGCGTTAGGAA   | AAAAGCATACCCGGAGAGAG   |
| VGLL3       | GGAGACATTGGTATCATGGG   | GGTATGCCACCTTCTCTAAT   |
| STAT1       | ATCAGGTCTAGTGCGGAAATA  | TGTATGCTCTTCCTCTCTTCT  |
| TNFSF13B    | GGGAGCATGCAGGCTCTAC    | GATCGGACAGAGGGCTTCT    |
| MIX1        | GGTTGGTCCCGAAGTTG      | CGTCAAGATTGCTTGACG    |
| IRF7        | CCACGGCTATACCTACCTACT  | GATGCTGCTATAGGGCTTGG   |
| OAS1        | TGCCAGGTTGTAAGGGTTG    | CCGGGAGTTAACGACTCTG    |
| TLR3        | CAAAACAAAAGATCTGGAACATCG | AAGGAATGCTTACACACACTT  |
| CCL5        | GCTGGTTAGTCATCACTG     | TCCGGTGCAAAGAGACGAC    |
| IFN-α1      | CTTTGCTGCTCGGAGGGTTGTC | TAGACAGGGTGAGAGAATTC   |
| IFN-β1      | GCTGGATACCTACAAGGAAGCA | ATAGATGCTCATTGCAGCGCT  |
RNA sequencing and data analysis

The purity of extracted RNA was examined by the kaiaoK5500® Spectrophotometer (Kaiao, Beijing, China). RNA integrity and concentration were evaluated using the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, CA, USA). Sequencing libraries were generated using NEBNext® Ultra™ RNA Library Prep Kit for Illumina® (#E7530L, NEB, USA) with 2 μg of total RNA per sample according to the manufacturer's instructions. The clustering of the index-coded samples was performed on a cBot cluster generation system using HiSeq PE Cluster Kit v4-cBot-HS (Illumina, CA, USA) following the manufacturer’s recommendations. After cluster generation, the libraries were sequenced on an Illumina platform and 150 bp paired-end reads were generated. Reads Count for each gene in each sample was counted by HISAT v2.0.5, and FPKM (fragments per kilobase per million mapped reads) was then calculated to estimate the expression level of genes in each sample. DEGseq v1.18.0 was used for differential gene expression analysis between two samples with nonbiological replicates. Genes with log2 fold change (log2(FC)) ≥ 1 and q value (false discovery rate or FDR) ≤ 0.05 were identified as differentially expressed genes (DEGs). Heatmaps for the selected DEGs were mapped by R package “pheatmap” in R studio. The expression levels of all the DEGs were shown as log2(FC). Gene set enrichment analysis (GSEA) for DEGs was performed using the RNA-seq data through WebGestalt as indicated [32], and the top 10 enriched gene sets were demonstrated.

Western blotting

Cells were lysed by RIPA buffer (Beyotime Biotechnology, Shanghai, China) on ice. Protein concentration was determined using a BCA protein assay kit (Beyotime Biotechnology, Shanghai, China). Denatured proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS–PAGE) and electrotransferred onto polyvinylidene fluoride (PVDF) membranes (Merck Millipore, MA, USA). Membranes were blocked by 10% bovine serum albumin (BSA) and incubated at 4°C overnight with rabbit anti-VGLL3 antibody (1:500, ab83555, Abcam, Cambridge, UK), rabbit anti-STAT1 antibody (1:10000, ab109320, Abcam, Cambridge, UK), rabbit anti-MX1 antibody (1:1000, 13750-1-AP, Proteintech, Wuhan, China), rabbit anti-IRF3 (phosphor S386) antibody (1:1000, ab76493, Abcam, Cambridge, UK), rabbit anti-IRF3 antibody (1:1000, ab68481, Abcam, Cambridge, UK), rabbit anti-YAP/WWTR1 antibody (1:1000, 8418, Cell Signaling Technology, MA, USA), rabbit anti-AMOTL2 antibody (1:500, 23351-1-AP, Proteintech, Wuhan, China), mouse anti-GAPDH antibody (1:5000, T0004, Affinity, OH, USA), and mouse anti-β-Tubulin (1:5000, T0023, Affinity, OH, USA). Next, membranes were washed with Tris-buffered saline (TBS) containing 0.1% Tween 20 and incubated with HRP-conjugated goat anti-rabbit antibody (1:5000, S0001, Affinity, OH, USA) or HRP-conjugated goat anti-mouse antibody (1:5000, S0002, Affinity, OH, USA). Protein bands were detected with ECL substrate (New Cell & molecular Biotech, Suzhou, China) and analyzed using ImageJ software.

Statistical analysis

All the experiments were conducted at least three times independently. Data were analyzed by IBM SPSS Statistics 22.0 and plotted using GraphPad Prism 8 software. Data were presented as mean ± SD. Student’s t-test was used for statistical comparison between two groups. One-way analysis of variance (ANOVA) followed by Dunnett’s T3 post hoc test was adopted for multiple comparisons. p-values < 0.05 were considered statistically significant.

Results

Upregulated expression of VGLL3 in RA-FLS

Immunohistochemistry staining was performed to examine the expression of VGLL3 in RA and OA synovium using anti-VGLL3 antibodies and rabbit IgG (isotype). Hematoxylin and eosin (HE) staining was conducted to evaluate the pathological changes. There were significant hyperplasia and leukocyte infiltration in the RA intimal lining layer comparing to OA, and VGLL3 expression was substantially upregulated in RA intimal lining layer (Fig. 1A). However, there was no significant difference in VGLL3 expression in the sublining layer between RA and OA (Fig 1A). Then, the FLS were isolated from RA synovium and subjected to immunofluorescence staining. The results showed that VGLL3 was expressed in both the cytoplasm and nucleus of RA-FLS (Fig. 1B). RT-PCR and qPCR analysis of RA-FLS and OA-FLS at passage 3 also indicated that the mRNA expression level of VGLL3 in RA-FLS was increased approximately by 100% compared with OA-FLS (Fig. 1C, D).

Regulation of type I IFN signature by VGLL3 in RA-FLS

To address the contribution of VGLL3 to ISGs expression in RA-FLS, VGLL3 was overexpressed in RA-FLS via a lentiviral vector. After 4 days of transfection, Flag-VGLL3-overexpressed RA-FLS and vector-transfected RA-FLS were subjected to RNA sequencing (n = 1). The expression levels of all the DEGs were shown as log2(FC) in the heatmap. The RNA expression levels of 1047 genes in total were altered by VGLL3 overexpression, including 357 genes upregulated and 690 genes downregulated (Fig. 2A). Subsequent GSEA revealed that response to type I IFN was the most
altered biological process in RA-FLS overexpressing VGLL3 (normalized enrichment score, 2.57, Fig. 2B).

Differential gene expression analysis showed that many ISGs were upregulated by VGLL3 overexpression, especially the type I ISGs (Fig. 2C). Real-time PCR verified the upregulation of ISGs (e.g., MX1, OAS1, STAT1, TNFSF13B, IRF7, TLR3, and CCL5) by VGLL3 (Fig. 2D). The protein expression levels of STAT1 and MX1 were also increased by VGLL3 overexpression (Fig. 2F). To exclude the influence on ISGs expression by virus infection, VGLL3 was further silenced by transfection of synthetic siRNA in RA-FLS. The mRNA expression of multiple ISGs and protein expression of STAT1 and MX1 were significantly inhibited after VGLL3 knockdown (Fig. 2E, G).

The expression levels of STAT1 and MX1 were correlated with VGLL3 in RA synovium
Next, the expression of STAT1 and MX1 in the OA and RA synovium was examined via IHC staining using anti-STAT1 antibody and anti-MX1 antibody. Isotype IgG was used as the negative control. Compared to OA, STAT1 and MX1 were substantially upregulated in the RA synovium (Fig. 3A, C). In both OA and RA patients, the percentage of VGLL3-positive cells had moderate correlations with that of STAT1-positive cells ($r = 0.5212$, $p < 0.05$, Fig. 3B) and was weakly correlated with the proportion of MX1-positive cells ($r = 0.2786$, $p < 0.05$, Fig. 3D). These data indicated that VGLL3 could determine the expression of STAT1 and MX1 in RA synovium to a certain extent.
VGLL3 facilitating the IRF3-mediated IFN-β production and autocrine signaling in RA-FLS

The mechanism that mediates the VGLL3-enhanced ISGs expression in RA-FLS remains unelucidated. Given that response to type I IFN was the predominantly modified biological process by VGLL3 overexpression, it was then explored whether VGLL3 changed the expression level of type I IFN. VGLL3 was overexpressed via a lentiviral vector or silenced by transfecting with VGLL3 siRNA in RA-FLS. The mRNA expression of IFN-α1 (gene name, IFNA1) and IFN-β1 (gene name, IFNB1) in RA-FLS after overexpression or knockdown of VGLL3 was examined via qPCR. VGLL3 overexpression significantly increased the expression of IFN-β1 in RA-FLS, but the expression of IFN-α1 was unaffected. Correspondingly, VGLL3 knockdown considerably decreased the IFN-β1 expression level, and the expression of IFN-α1 was only moderately inhibited (Fig. 4A). These results indicated that VGLL3 might enhance the expression of ISGs in RA-FLS by facilitating IFN-β1 production. IRF3 is a master transcription factor for IFN-β expression. The nuclear translocation and phosphorylation of IRF3 were further examined by immunofluorescence staining after overexpression of VGLL3. Nuclei were stained with DAPI. The results showed that overexpression of VGLL3 markedly increased the protein level of IRF3 in the nuclei of RA-FLS (Fig. 4B), and the phosphorylation of IRF3 in RA-FLS was also enhanced by overexpression of VGLL3 as shown by Western blotting (Fig. 4C). STAT1 could be phosphorylated and activated upon IFN-β stimulation and translocated into the nuclear to activate the expression of ISGs. It was found that overexpression of VGLL3 promoted the phosphorylation of STAT1 (Fig. 4D), indicating the activation of STAT1. To verify that the elevated level of IFN-β1 after overexpression of VGLL3 was accountable for the increased expression of ISGs, a Janus kinase (JAK) inhibitor tofacitinib was
used to block the intracellular signaling transduction of the IFN-β1 receptor IFNAR. RA-FLS were transfected with Flag-VGLL3-expressing lentivirus with/without the treatment of JAK inhibitor tofacitinib (250 nM). The results demonstrated that VGLL3 overexpression-augmented mRNA expression levels of ISGs (STAT1, BAFF, MX1, IRF7, OAS1, TLR3, and CCL5) were suppressed by tofacitinib (250 nM) (Fig. 4E). And immunofluorescence staining showed that tofacitinib (250 nM) significantly inhibited the expression of STAT1 induced by VGLL3 overexpression (Fig. 4F). The above findings indicated that VGLL3 facilitated the IRF3-mediated IFN-β1 production in RA-FLS, and IFN-β1 might stimulate the expression of ISGs in an autocrine manner.

**VGLL3 exacerbated IFN-β1 production by inhibiting Hippo pathway**

To explore the mechanism by which VGLL3 regulates the IFN-β1 production in RA-FLS, proteins involved in the Hippo pathway were examined. Western blotting showed that the protein expression level of WWTR1 was enhanced by VGLL3 knockdown, and the expression of AMOTL2 was inhibited (Fig. 5A). In contrast, overexpression of VGLL3 markedly suppressed the expression of WWTR1 and increased the expression of AMOTL2 (Fig. 5B). Transfection of WWTR1 siRNA into RA-FLS silenced the expression of WWTR1, as verified by Western blotting (Fig. 5C). The reduction of IFN-β1 mRNA expression level induced by VGLL3 silencing was partially rescued by WWTR1 siRNA transfection (Fig. 5D). Furthermore, WWTR1 siRNA transfection could also restore the nuclear translocation of IRF3 and the expression of STAT1 which were inhibited by VGLL3 silencing in RA-FLS (Fig. 5E, F), suggesting that VGLL3 regulates the IRF3 nuclear translocation and IFN-β1 expression through the Hippo pathway.

**Discussion**

Recently, the role of VGLL3 in autoimmune diseases has drawn much attention. VGLL3-regulated gene network has been demonstrated as a promoter of sex-biased autoimmune diseases, including lupus, systemic sclerosis,
and Sjögren’s syndrome. Elevated expression of VGLL3 was discovered in normal female skin and keratinocytes compared to males and also in the skin of SLE patients compared to healthy controls [28]. VGLL3-overexpressing mice had higher rates of developing lupus-like cutaneous phenotype [33]. As is well known that RA is a sex-biased autoimmune disease. The estimated ratio of the prevalence in females against males ranged from 3:1 to 4:1 in different countries [34–36]. Our data demonstrated that the expression of VGLL3 was higher in the RA synovium and RA-FLS compared to OA.

In human keratinocytes and monocytes, VGLL3 was required for the optimal expression of ITGAM and TNFSF13B, which are pro-inflammatory genes related to the pathogenesis of RA. The expression of these genes was detected by qPCR and Western blotting in RA-FLS. The results showed a significant increase in the expression of ITGAM and TNFSF13B upon VGLL3 overexpression.

**Fig. 4** Activation of IRF3 and augmentation of IFN-β1 expression by VGLL3 in RA-FLS. 

a) The mRNA expression levels of IFN-α1 and IFN-β1 were detected by qPCR after VGLL3 overexpression or knockdown in RA-FLS. 

b) Representative images of the expression of IRF3 in RA-FLS examined by immunofluorescence staining. 

C) The protein expression levels of p-IRF3 and total IRF3 in RA-FLS were detected by Western blotting upon VGLL3 overexpression. GAPDH was used as the housekeeping gene. 

d) The protein expression levels of p-STAT1 in RA-FLS were detected by Western blotting. 

e) Gene expression levels of STAT1, TNFSF13B, MX1, IRF7, OAS1, TLR3, and CCL5 were detected in RA-FLS transfected with Flag-VGLL3-expressing lentivirus with or without the treatment of Janus kinase inhibitor tofacitinib (250 nM). 

f) Representative images of the expression of STAT1 in RA-FLS transfected with Flag-VGLL3-expressing lentivirus with or without the treatment of tofacitinib (250 nM) examined by immunofluorescence staining. Nuclei were stained with DAPI. Scale bar, 100 μm. N = 3. *p < 0.05, **p < 0.01, ***p < 0.001
to SLE [28]. Meanwhile, VGLL3 overexpression in mice elevated the expression of cutaneous lupus-related genes, including TNFSF13B, IFN-κ, and CXCL13 [33]. Our study revealed that VGLL3 predominantly regulated ISGs (especially type I ISGs) in RA-FLS, including STAT1, TNFSF13B, MX1, OAS1, IFI6, IFIT1, ISG15, LY6E, IFITM3, IRF7, and RSAD2. Genes involved in the Toll-like receptor signaling pathway such as TLR3 and MYD88, and chemokines such as CCL5 was also regulated by VGLL3. STAT1 is one of the master signal transducers in the process of cellular responses to IFNs. Upon stimulation of IFNs, the cellular expression of STAT1 is also increased because the upstream regulatory region of STAT1 contains IFN-stimulated response elements and GAS sites, making STAT1 an ISG [37]. STAT1 was implicated in the inflammatory phenotype in RA-FLS and mouse embryonic fibroblasts [38]. There was evidence that TNFSF13B was involved in

---

**Fig. 5** VGLL3 exacerbated IFN-β1 production by inhibiting Hippo pathway. a Representative images of the protein expression of WWTR1 and AMOTL2 in RA-FLS transfected with VGLL3 siRNA or Scr siRNA examined by Western blotting. β-Tubulin was used as the housekeeping gene. b Representative images of the protein expression of WWTR1 and AMOTL2 in RA-FLS transfected with Flag-VGLL3 expressing lentivirus or vector examined by Western blotting. GAPDH was used as the housekeeping gene. c Representative images of the protein expression of WWTR1 in RA-FLS transfected with WWTR1 siRNA or Scr siRNA examined by Western blotting. GAPDH was used as the housekeeping gene. d–f The mRNA expression levels of IFN-β1 (d) examined by real-time PCR and protein expression of IRF3 (e) and STAT1 (f) examined by immunofluorescence staining in RA-FLS transfected with Scr siRNA, VGLL3 siRNA, and WWTR1 siRNA + VGLL3 siRNA. N = 3. *p < 0.05, **p < 0.01, ***p < 0.001. Data were shown as mean ± SD.
RA pathogenesis. The protein levels of TNFSF13B were increased in the serum and synovial fluid of RA patients [39]. It increased the expression of pro-inflammatory cytokines such as IL-1 and IL-6 and enhanced the differentiation of T cells into TH17 cells [10]. Bioinformatics analysis indicated that RSAD2, OAS2, MX1, and ISG15 might be remarkable gene signatures in RA development by regulating immune responses [40]. Our results also proved that the expression of STAT1 and MX1 in RA synovium was higher than that in OA. STAT1 and MX1 expression levels correlated positively with VGLL3 in the RA synovium, respectively. Thus, VGLL3 might be implicated in RA pathogenesis through VGLL3-regulated genes.

To explain how VGLL3 regulated the expression of ISGs, the expression of type I IFNs was detected in RA-FLS. It has been testified that human fibroblasts produce IFN-β upon stimulation [41]. Intriguingly, our data revealed that IFN-β1 expression was strikingly regulated upon VGLL3 overexpression or knockdown in RA-FLS. This differed from the previous studies where VGLL3 overexpression failed to disturb the IFN-β expression in mouse skin [33], indicating that the VGLL3-regulated gene spectrum might vary in different cellular or disease context. The transcription factor IRF3 plays a pivotal role in the expression of IFN-β. Upon activation, IRF3 gets phosphorylated, moves into the nucleus, and transactivates the transcription of IFN-β by binding to its promoter region [42–44]. We found that VGLL3 overexpression triggered the phosphorylation and nuclear translocation of IRF3. JAK1 is the intracellular adaptor and signal transducer of IFNAR [5]. Tofacitinib selectively inhibits JAK1 and JAK3 [45], thus blocking the signals of type I IFNs binding to IFNAR. Importantly, our results suggested that blocking type I IFN signaling with Tofacitinib strongly repressed the VGLL3-induced ISGs expressions, indicating that VGLL3 might drive the IFN-β1 expression by activating IRF3 and secreted IFN-β1 stimulated the ISGs expression in RA-FLS in an autocrine manner.

It has been reported that YAP/WWTR1, which is the core protein of the Hippo pathway, antagonized the IFN-β expression by inhibiting the activation of IRF3 [46]. VGLL3 could activate the Hippo pathway and promote cell proliferation in A549 cells and MDA-MB-231 cells [27]. In our study, we found that VGLL3 knockdown could elevate the expression of WWTR1 in RA-FLS but had no influence on the expression of YAP (data not shown). In contrast, VGLL3 overexpression inhibited the expression of WWTR1 as expected. The angiomotin (AMOT) family could inhibit the nuclear translocation of YAP/WWTR1, acting as a novel Hippo pathway component [47]. Our results showed that the potent YAP/WWTR1 inhibitor AMOTL2 was inhibited after VGLL3

![Diagram](image-url)
knockdown. Silencing WWTR1 with siRNA blocked the inhibitory effect of VGLL3 knockdown on IFN-β1 production in RA-FLS, suggesting that VGLL3 might regulate the IFN-β1 expression through the AMOTL2-WWTR1-IRF3 pathway.

Conclusions
VGLL3 drives the IRF3-induced IFN-β1 secretion in RA-FLS by inhibiting WWTR1 expression and subsequently promotes the type I IFN signature expression through autocrine IFN-β1 signaling (Fig. 6). These results provide novel insights into how the type I IFN signature are regulated in RA-FLS and make VGLL3 a possible RA therapeutic target.

Abbreviations
AMOT: Angiomotin; ANOVA: Analysis of variance; BAFF: B cell-activating factor; BSA: Bovine serum albumin; DAB: Diaminobenzidine; DAPI: 4,6-Diamidino-2-phenylindole; DEGs: Differentially expressed genes; DREM: Dublecco’s Modified Eagle Medium; FLS: Fibroblast-like synoviocytes; FPKM: Fragments per kilobase per million mapped reads; GSEA: Gene set enrichment analysis; H: Hematoxylin; I: Interferon; IFN: Interferon; IFNAR: IFN-α receptor; IRF9: IFN regulatory factor 9; ISGF3: IFN-stimulated gene factor 3; ISGs: IFN-stimulated genes; JAK: Janus kinase; LAT51/2: Large tumor suppressor kinase 1/2; log2(FC): log2 fold change; OA: Osteoarthritis; P: Paraformaldehyde; PVDF: Polyvinylidene fluoride; qPCR: Quantitative PCR; RA: Rheumatoid arthritis; RT-PCR: Reverse transcription PCR; S: Systemic lupus erythematosus; STAT1: Signal transducer and activator of transcription 1; TAZ: Transcriptional coactivator with PDZ-binding motif; TEADs: TEA domain-containing transcription factors; TNFSF13B: Tumor necrosis factor ligand superfamily member 3; WWTR1: WW domain-containing transcription regulator 1; YAP: Yes-associated protein.

Acknowledgements
We appreciate the contribution of Prof. Si-feng Chen (Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, China) on the scientific advice and technical assistance.

Authors’ contributions
Y.D. and S.D. performed the study concept and design; Y.D., R.C., and S.D. performed the study; Y.D., R.C., and S.D. provided acquisition, analysis and interpretation of data, and statistical analysis; X.Z., N.T., and M.C. provided technical and material support. The authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (grant numbers 81771746 and 82071809).

Availability of data and materials
The raw data and FPKM data of RNA-sequencing generated during the current study are available in NIH Gene Expression Omnibus (GEO; accession number GSE200030). All other data generated during the current study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
Informed consent was obtained from all patients before sample collection. This study complied with the Declaration of Helsinki (1964), and the research was approved by the Ethic Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Rheumatology and Immunology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai 200333, China. 2 Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China.

Received: 31 March 2022 Accepted: 23 July 2022
Published online: 08 August 2022

References
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–38.
2. Kaibara N, Yamada H, Shuto T, Nakashima Y, Okazaki K, Miyahara H, et al. Comparative histopathological analysis between tenosynovitis and joint synovitis in rheumatoid arthritis. Histopathology. 2008;52:856–64.
3. Conigliaro P, Perricone C, Benson RA, Garside P, Brewer JM, Perricone R, et al. The type I IFN system in rheumatoid arthritis. Autoimmunity. 2010;43:220–5.
4. Yoshida S, Arakawa F, Higuchi F, Ishibashi Y, Goto M, Sugita Y, et al. Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scand J Rheumatol. 2012;41:170–9.
5. Iwashiki LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36–49.
6. Hertzog P, Forster S, Samarajiwa S. Systems biology of interferon responses. J Interferon Cytokine Res. 2011;31:5–11.
7. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, et al. Interferon v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41:D1040–D6.
8. Rodriguez-Cardio J, Lópe P, Suárez A. Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine. Clin Sci. 2015;128:449–64.
9. Asquith DL, Bryce SA, Nibbs RJ. Targeting cell migration in rheumatoid arthritis. Curr Opin Rheumatol. 2015;27:204–11.
10. Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M. The role of BAFF and APRIL in rheumatoid arthritis. J Cell Physiol. 2019;234:17050–63.
11. Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, van Baarsen LG, Wijbrandts CA, Voskuyl AE. Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients. Genes Immun. 2008;9:16–22.
12. Gordon RA, Greigrov G, Lee A, Kalliossis GD, Iwashiki LB. The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment. Arthritis Rheum. 2012;64:3119–28.
13. Rosengren S, Cor M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis. 2012;71:440–7.
14. Higgs BW, Liu Z, White W, Zhu W, White WL, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70:2029–36.
15. Staleane KN, Björklund A, Wisborg K, Reseland JE, Gravallese EM, Brodal E, et al. Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients. Genes Immun. 2007;66:1008–14.
16. van der Pouw Kraan TC, van Baarsen LG, Wijbrantsda CA, Voskuyl AE, Rustenburg F, Baggen JM, et al. Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients. Genes Immun. 2007;66:1008–14.
17. Lübbers J, Brink M, van de Stadt LA, Vosslander S, Wesseling JG, van Schaardenburg D, et al. The type I interferon signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis. 2013;72:776–80.

18. Thurlings WM, Boumans M, Tekstra J, van Rooij JA, Vos K, van Westing DM, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62:3607–14.

19. Wang S, Zhou L, Ling L, Meng X, Chu F, Zhang S, et al. The crosstalk between Hippo-YAP pathway and innate immunity. Front Immunol. 2020;11:323.

20. Morishita T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15:73–9.

21. Yu FX, Zhao B, Guan KL. Hippo Pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811–28.

22. Zhang Q, Meng F, Chen S, Plouffe SW, Wu S, Liu S, et al. Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade. Nat Cell Biol. 2017;19:662–74.

23. Mesrouye Y, Aguilar G, Bokhovchuk F, Martin T, Delauvay C, Villard F, et al. A new perspective on the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors. Sci Rep. 2020;10:17442.

24. Gambaro K, Quinn MC, Wojnarowicz P, Arcand SL, de Ladurantaye M, Barrès V, et al. VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer. Mol Oncol. 2013;7:513–30.

25. Pigeau N, Mohamed AD, Sun C, Schönfelder M, Matallanas D, García-Munoz A, et al. VGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscle. J Cell Sci. 2019;132:jcs225946.

26. Halperin DS, Pan C, Lusis AJ, Tontonoz P. Vestigial-like 3 is an inhibitor of adipocyte differentiation. J Lipid Res. 2013;54:747–83.

27. Hori N, Okada K, Takakura Y, Takano H, Yamaguchi N, Yamaguchi N. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway. J Biol Chem. 2020;295:8798–807.

28. Liang Y, Tsoi LC, Xing X, Beamer MA, Swindell WR, Sarkar MK, et al. A gene network regulated by the transcription factor VGLL3 as a promoter of sex‑biased autoimmune diseases. Nat Immunol. 2017;18:152–60.

29. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.

30. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29:1039–49.

31. Du Y, Wang Q, Tian N, Lu M, Zhang XL, Dai SM. Knockdown of nrfl2 exacerbates TNF-α‑induced Proliferation and Invasion of Rheumatoid Arthritis Fibroblast‑Like Synoviocytes through Activating JNK Pathway. J Immunol Res. 2020;2020:6670464.

32. Liao Y, Wang J, Jaehng EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped Uls and APIs. Nucleic Acids Res. 2019;47:W199–205.

33. Billi AC, Gharaei‑Kermani M, Fullmer J, Tsoi LC, Hill BD, Gruszka D, et al. The female‑biased factor VGLL3 drives cutaneous and systemic autoimmunity. JCI Insight. 2019;4:e127291.

34. Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int. 2017;37:1551–7.

35. Xiang YJ, Dai SM. Prevalence of rheumatic diseases and disability in China. Rheumatol Int. 2009;29:481–90.

36. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316–22.

37. Yuasa K, Hijikata T. Distal regulatory element of the STAT1 gene potentially mediates positive feedback control of STAT1 expression. Genes Cells. 2016;21:25–40.

38. Wang S, Wang L, Wu C, Sun S, Pan JH. E2F2 directly regulates the STAT1 and PI3K/AKT/NF‑κB pathways to exacerbate the inflammatory phenotype in rheumatoid arthritis synovial fibroblasts and mouse embryonic fibroblasts. Arthritis Res Ther. 2018;20:225.

39. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, et al. Concentrations of BAFF correlate with autoimmune levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol. 2008;35:1256–64.

40. He P, Zhang Z, Liao W, Xu D, Fu M, Kang Y. Screening of gene signatures for rheumatoid arthritis and osteoarthritis based on bioinformatics analysis. Mol Med Rep. 2016;14:1587–93.

41. Sano E, Ohashi K, Sato Y, Kashiwagi M, Joguchi A, Naruse N. A possible role of autogenous IFN-beta for cytokine productions in human fibroblasts. J Cell Biochem. 2007;100:1459–76.

42. Sin WX, Li P, Yeong JP, Chin KC. Activation and regulation of interferon-β in immune responses. Immunol Res. 2012;53:25–40.

43. Chessler AD, Ferreira LR, Chang TH, Fitzgerald KA, Burleigh BA. A novel IFN regulatory factor 3‑dependent pathway activated by trypanosomes triggers IFN-beta in macrophages and fibroblasts. J Immunol. 2008;181:7917–24.

44. López de Padilla CM, Niewold TB. The type I interferons: basic concepts and clinical relevance in immune‑mediated inflammatory diseases. Gene. 2016;576:14–21.

45. Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017;77:1987–2001.

46. Wang S, Xie F, Chu F, Zhang Z, Yang B, Dai T, et al. YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKe‑mediated phosphorylation. Nat Immunol. 2017;18:733–43.

47. Zhao B, Li S, Lu Q, Wang LH, Lu CY, Lei Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011;25:51–63.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.